|
1
|
Greenlee H, DuPont-Reyes MJ, Balneaves LG,
Carlson LE, Cohen MR, Deng G, Johnson JA, Mumber M, Seely D, Zick
SM, et al: Clinical practice guidelines on the evidence-based use
of integrative therapies during and after breast cancer treatment.
CA Cancer J Clin. 67:194–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Polychemotherapy for early breast cancer:
An overview of the randomised trials. Early Breast Cancer
Trialists' Collaborative Group. Lancet. 352:930–942. 1998.
|
|
4
|
Antoine M, Wirz W, Tag CG, Mavituna M,
Emans N, Korff T, Stoldt V, Gressner AM and Kiefer P: Expression
pattern of fibroblast growth factors (FGFs), their receptors and
antagonists in primary endothelial cells and vascular smooth muscle
cells. Growth Factors. 23:87–95. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diez Del Corral R and Morales AV: The
Multiple roles of FGF signaling in the developing spinal cord.
Front Cell Dev Biol. 5:582017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Majidinia M, Sadeghpour A and Yousefi B:
The roles of signaling pathways in bone repair and regeneration. J
Cell Physiol. 233:2937–2948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Presta M, Chiodelli P, Giacomini A,
Rusnati M and Ronca R: Fibroblast growth factors (FGFs) in cancer:
FGF traps as a new therapeutic approach. Pharmacol Ther.
179:171–187. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Itoh N and Ornitz DM: Evolution of the Fgf
and Fgfr gene families. Trends Genet. 20:563–569. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elo T, Lindfors PH, Lan Q, Voutilainen M,
Trela E, Ohlsson C, Huh SH, Ornitz DM, Poutanen M, Howard BA, et
al: Ectodysplasin target gene Fgf20 regulates mammary bud growth
and ductal invasion and branching during puberty. Sci Rep.
7:50492017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng S, Wang J, Zhang Y, Creighton CJ and
Ittmann M: FGF23 promotes prostate cancer progression. Oncotarget.
6:17291–17301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu XL, Gu MM, Huang L, Liu XS, Zhang HX,
Ding XY, Xu JQ, Cui B, Wang L, Lu SY, et al: Multiple synostoses
syndrome is due to a missense mutation in exon 2 of FGF9
gene. Am J Hum Genet. 85:53–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ohbayashi N, Shibayama M, Kurotaki Y,
Imanishi M, Fujimori T, Itoh N and Takada S: FGF18 is required for
normal cell proliferation and differentiation during osteogenesis
and chondrogenesis. Genes Dev. 16:870–879. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sonvilla G, Allerstorfer S, Stättner S,
Karner J, Klimpfinger M, Fischer H, Grasl-Kraupp B, Holzmann K,
Berger W, Wrba F, et al: FGF18 in colorectal tumour cells:
Autocrine and paracrine effects. Carcinogenesis. 29:15–24. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei W, Mok SC, Oliva E, Kim SH, Mohapatra
G and Birrer MJ: FGF18 as a prognostic and therapeutic biomarker in
ovarian cancer. J Clin Invest. 123:4435–4448. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shimokawa T, Furukawa Y, Sakai M, Li M,
Miwa N, Lin YM and Nakamura Y: Involvement of the FGF18 gene
in colorectal carcinogenesis, as a novel downstream target of the
beta-catenin/T-cell factor complex. Cancer Res. 63:6116–6120.
2003.PubMed/NCBI
|
|
16
|
MacCorkle RA and Tan TH: Mitogen-activated
protein kinases in cell-cycle control. Cell Biochem Biophys.
43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin GS: Cell signaling and cancer.
Cancer Cell. 4:167–174. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kohno M and Pouyssegur J: Targeting the
ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baudino TA, McKay C, Pendeville-Samain H,
Nilsson JA, Maclean KH, White EL, Davis AC, Ihle JN and Cleveland
JL: c-Myc is essential for vasculogenesis and angiogenesis during
development and tumor progression. Genes Dev. 16:2530–2543. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao DJ and Dickson RB: c-Myc in breast
cancer. Endocr Relat Cancer. 7:143–164. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neelakantan D, Zhou H, Oliphant MU, Zhang
X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et
al: EMT cells increase breast cancer metastasis via paracrine GLI
activation in neighbouring tumour cells. Nat Commun. 8:157732017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maeda M, Johnson KR and Wheelock MJ:
Cadherin switching: Essential for behavioral but not morphological
changes during an epithelium-to-mesenchyme transition. J Cell Sci.
118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Canesin G, Cuevas EP, Santos V,
López-Menéndez C, Moreno-Bueno G, Huang Y, Csiszar K, Portillo F,
Peinado H, Lyden D and Cano A: Lysyl oxidase-like 2 (LOXL2) and E47
EMT factor: Novel partners in E-cadherin repression and early
metastasis colonization. Oncogene. 34:951–964. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neal CL, Henderson V, Smith BN, McKeithen
D, Graham T, Vo BT and Odero-Marah VA: Snail transcription factor
negatively regulates maspin tumor suppressor in human prostate
cancer cells. BMC Cancer. 12:3362012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blanckaert VD, Hebbar M, Louchez MM,
Vilain MO, Schelling ME and Peyrat JP: Basic fibroblast growth
factor receptors and their prognostic value in human breast cancer.
Clin Cancer Res. 4:2939–2947. 1998.PubMed/NCBI
|
|
28
|
Cai Y, Zhang J, Lao X, Jiang H, Yu Y, Deng
Y, Zhong J, Liang Y, Xiong L and Deng N: Construction of a
disulfide-stabilized diabody against fibroblast growth factor-2 and
the inhibition activity in targeting breast cancer. Cancer Sci.
107:1141–1150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen T, Gong W, Tian H, Wang H, Chu S, Ma
J, Yang H, Cheng J, Liu M, Li X and Jiang C: Fibroblast growth
factor 18 promotes proliferation and migration of H460 cells via
the ERK and p38 signaling pathways. Oncol Rep. 37:1235–1242. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koneczny I, Schulenburg A, Hudec X,
Knöfler M, Holzmann K, Piazza G, Reynolds R, Valent P and Marian B:
Autocrine fibroblast growth factor 18 signaling mediates
Wnt-dependent stimulation of CD44-positive human colorectal adenoma
cells. Mol Carcinog. 54:789–799. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang XL, Liu KY, Lin FJ, Shi HM and Ou ZL:
CCL28 promotes breast cancer growth and metastasis through
MAPK-mediated cellular anti-apoptosis and pro-metastasis. Oncol
Rep. 38:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hrustanovic G, Olivas V, Pazarentzos E,
Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS,
Sabnis A, et al: RAS-MAPK dependence underlies a rational
polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med.
21:1038–1047. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Urosevic J, Garcia-Albéniz X, Planet E,
Real S, Céspedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S,
Pavlovic M, et al: Colon cancer cells colonize the lung from
established liver metastases through p38 MAPK signalling and PTHLH.
Nat Cell Biol. 16:685–694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Whyte J, Bergin O, Bianchi A, McNally S
and Martin F: Key signalling nodes in mammary gland development and
cancer. Mitogen-activated protein kinase signalling in experimental
models of breast cancer progression and in mammary gland
development. Breast Cancer Res. 11:2092009.
|
|
35
|
Wilde BR and Ayer DE: Interactions between
Myc and MondoA transcription factors in metabolism and
tumourigenesis. Br J Cancer. 113:1529–1533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fallah Y, Brundage J, Allegakoen P and
Shajahan-Haq AN: MYC-driven pathways in breast cancer subtypes.
Biomolecules. 7:E532017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nelson WJ and Nusse R: Convergence of Wnt,
beta-catenin, and cadherin pathways. Science. 303:1483–1487. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang JJ, Li ZF, Li XJ, Han Z, Zhang L and
Liu ZJ: Effects of microRNA-136 on melanoma cell proliferation,
apoptosis and epithelial mesenchymal transition by targeting PMEL
through the Wnt signaling pathway. Biosci Rep. 37:BSR20170743.
2017. View Article : Google Scholar
|
|
40
|
Derynck R, Muthusamy BP and Saeteurn KY:
Signaling pathway cooperation in TGF-β-induced
epithelial-mesenchymal transition. Curr Opin Cell Biol. 31:56–66.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
